Instil Bio (TIL) Other Non-Current Liabilities (2021 - 2026)
Instil Bio (TIL) posted quarterly Other Non-Current Liabilities of $8000.0 for Q1 2026, down 90.59% year-over-year from $85000.0 in Q1 2025, and little changed quarter-over-quarter from $8000.0 in Q4 2025.
Instil Bio (TIL) Other Non-Current Liabilities (2021 - 2026) Analysis & Trends
Instil Bio's Other Non-Current Liabilities history runs 6 years deep, the most recent figure standing at $8000.0 for Q1 2026.
- In Q1 2026, Other Non-Current Liabilities fell 90.59% year-over-year to $8000.0; the TTM figure through Mar 2026 stood at $8000.0 (down 90.59% YoY), while the FY2025 annual figure was $8000.0, down 90.36% from the prior year.
- Other Non-Current Liabilities for Q1 2026 stood at $8000.0, roughly flat from $8000.0 in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $10.4 million in Q2 2022, with the low at $8000.0 in Q2 2024.
- The 5-year median for Other Non-Current Liabilities is $196000.0 (2023), against an average of $1.9 million.
- Peak annual rise in Other Non-Current Liabilities reached 2428.06% in 2024, while the deepest fall reached 99.9% in 2024.
- Instil Bio's Other Non-Current Liabilities stood at $332000.0 in 2022, then soared by 1363.25% to $4.9 million in 2023, then tumbled by 98.29% to $83000.0 in 2024, then slumped by 90.36% to $8000.0 in 2025, then changed by 0.0% to $8000.0 in 2026.
- Business Quant data shows TIL's Other Non-Current Liabilities at $8000.0 in Q1 2026, $8000.0 in Q4 2025, and $948000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.71 Bn | 131.86 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.87 Bn | 78.87 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.40 Bn | 60.22 Bn | 1.37 Bn |
| 4 | Moderna | 59.36 Bn | 54.22 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.12 Bn | 37.02 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.91 Bn | 28.60 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.17 Bn | 9.78 Bn | 668.28 Mn |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - |
| 10 | Instil Bio | 53.44 Mn | 53.44 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8,000.00 |
| Dec 31, 2025 | 8,000.00 |
| Sep 30, 2025 | 948,000.00 |
| Jun 30, 2025 | 90,000.00 |
| Mar 31, 2025 | 85,000.00 |
| Dec 31, 2024 | 83,000.00 |
| Sep 30, 2024 | 2.36 Mn |
| Jun 30, 2024 | 8,000.00 |
| Mar 31, 2024 | 4.96 Mn |
| Dec 31, 2023 | 4.86 Mn |
| Sep 30, 2023 | 115,000.00 |
| Jun 30, 2023 | 8.04 Mn |
| Mar 31, 2023 | 196,000.00 |
| Dec 31, 2022 | 332,000.00 |
| Sep 30, 2022 | 375,000.00 |
| Jun 30, 2022 | 10.41 Mn |
| Mar 31, 2022 | 20,000.00 |
| Dec 31, 2021 | 20,000.00 |
| Sep 30, 2021 | 10.88 Mn |
| Jun 30, 2021 | 1.11 Mn |